Earnings summaries and quarterly performance for Adverum Biotechnologies.
Executive leadership at Adverum Biotechnologies.
Board of directors at Adverum Biotechnologies.
Research analysts who have asked questions during Adverum Biotechnologies earnings calls.
Alethia Young
Cantor Fitzgerald
4 questions for ADVM
Philip Nadeau
TD Cowen
4 questions for ADVM
Graig Suvannavejh
Mizuho Securities
3 questions for ADVM
Mani Foroohar
Leerink Partners
3 questions for ADVM
Tyler Van Buren
TD Cowen
3 questions for ADVM
Luca Issi
RBC Capital Markets
2 questions for ADVM
Patrick Dolezal
LifeSci Capital
2 questions for ADVM
Dane Leone
Raymond James
1 question for ADVM
Joon Lee
Truist Securities
1 question for ADVM
Tara Bancroft
TD Cowen
1 question for ADVM
Recent press releases and 8-K filings for ADVM.
- On December 4, 2025, Adverum Biotechnologies, Inc. announced positive two-year long-term follow-up data from its LUNA Phase 2 clinical trial of Ixo-vec in patients with wet age-related macular degeneration (AMD).
- Ixo-vec demonstrated a consistent ~90% reduction in mean annualized anti-VEGF injection burden over two years, with rates dropping from approximately 10 injections in the prior year to 1.1 in the 6E10 group and 0.9 in the 2E11 group.
- The therapy showed sustained anatomic control and best corrected visual acuity through two years and was well tolerated, with no new inflammation observed after week 30 in participants receiving the 6E10 dose and local prophylaxis.
- The company anticipates completing full enrollment for its pivotal Phase 3 ARTEMIS trial on December 5, 2025, having enrolled 110% of the original target. Topline data for this trial is anticipated in Q1 2027.
- Eli Lilly and Company announced a definitive agreement to acquire Adverum Biotechnologies, Inc..
- The acquisition offers $3.56 per share in cash at closing, plus one non-transferrable contingent value right (CVR).
- The CVR could provide up to an additional $8.91 per CVR upon the achievement of two milestones, resulting in a total potential per share consideration of up to $12.47.
- The CVR milestones include U.S. approval of Ixo-vec (up to $1.78 per CVR) and annual worldwide net sales of Ixo-vec exceeding $1.0 billion (up to $7.13 per CVR).
- Ixo-vec, Adverum's lead program, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration (wAMD). The transaction is expected to close in the fourth quarter of 2025.
- Adverum Biotechnologies, Inc. has completed screening for its pivotal Phase 3 ARTEMIS trial, which evaluates Ixo-vec for wet age-related macular degeneration (wet AMD).
- The completion of screening occurred ahead of expectations.
- Full enrollment for the ARTEMIS trial is now anticipated in Q4 2025, an acceleration from the previous expectation of Q1 2026.
- The topline data readout for the ARTEMIS trial has been accelerated to Q1 2027.
Quarterly earnings call transcripts for Adverum Biotechnologies.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more